Kura Oncology, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
Mailing Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
Phone
(858) 500-8800
Fiscal Year End
1231
EIN
611547851
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Kura Oncology is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer.
- Its lead product candidate, ziftomenib, is an investigational menin inhibitor currently in clinical trials for acute myeloid leukemia (AML).
Insider Trading
STRONG SELL
7 insiders
18 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.